1. In Vivo
  2. >>Business Strategy

Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.

While the press surrounding Pfizer Inc. 's acquisition of privately held Angiosyn Inc. in mid-January suggested a $527 million blockbuster deal for the tiny California biotech, the immediate financial reality behind the biobucks headlines was slightly more mundane [See Deal].

Angiosyn was formed in May 2003 by the Scripps Research Institute's Paul Schimmel, PhD, with backing from venture firm Alta...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

CellProthera Targeting Heart Regeneration Where No Treatment Exists

 
• By David Wild

French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.

Patient-Centric Strategy Drives Memo Therapeutics Forward

 
• By Anabel Costa-Ferreira

Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.

Small Biotech, Big Breakthrough: Abivax Enters A New Era

 
• By Lucie Ellis-Taitt

Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.

More from In Vivo

Execs On The Move: October 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

A $30m Milestone And Leadership Handoff Signal New Chapter For Recursion

 
• By David Wild

Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.

How Rare Disease Advocates Are Reshaping Gene Therapy Development

 
• By David Wild

Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.